EMA tovorafenib coverage for business development, investment, and market access teams
Earlier
High impact NewsApr 23, 2026
Ipsen Receives EU Approval for Ojemda (Tovorafenib) to Treat Pediatric Brain Cancer with BRAF Mutations
Pediatric Oncology · 3 min
Sofia AlvarezHigh impact NewsApr 22, 2026
Ipsen's Ojemda (Tovorafenib) Becomes First Targeted Therapy for Pediatric Brain Tumors in EU
Pediatric Oncology - Low-Grade Glioma · 3 min
Dr. Elena RossiPopular topics
- Drug Approvals 1,128 articles
- Clinical Trials 634 articles
- Regulatory Updates 687 articles
- Press Releases 443 articles
- Oncology 443 articles
- Mergers & Acquisitions 105 articles
- Rare Diseases 141 articles
Explore intelligence
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways